NattoPharma

News and Media

Event calendar

2012

Article on the Effect of MenaQ7 Natural Vitamin K2 published by the American Journal of Kidney Disease

In a press release on December 10, 2009 Nattopharma announced the first use of MenaQ7, the natural vitamin K2, as an intervention in a placebo controlled clinical trial on dialysis patients. The aim of the study was to assess the effects of natural vitamin K2 on vascular health parameters in a patient group that has a very high degree of risk for cardiovascular disease.

Read more »

Positive results on “Clinical trial on beneficial effects of long term MenaQ7® intake by postmenopausal women”

In 2007 NattoPharma initiated a 3-year clinical intervention study on the effects of MenaQ7® on bone and cardiovascular health, respectively. Recruitment for the study started in early 2008 and the last measurements have been completed in the fall of 2011. The compliance was excellent - with 91.4% of the randomized participants staying in the study until its completion. The data are presently evaluated but already it may be concluded that the results are positive and that the primary efficacy parameters are met.

Read more »

Findings from new 3 year clinical trial presented for the first time at Vitafoods Geneva, May 22nd

Don’t miss the opportunity to listen to Professor Cees Vermeer present the outcomes of the 3-year clinical trial investigating beneficial effects of natural vitamin K2 (MenaQ7) on bone and vascular health.

MenaQ7 is the first Vitamin K supplement with demonstrated health effects at nutritionally relevant doses.

Read more »

For the Press

Press inquire:

Kate Quackenbush
Director of Communications
kate.quackenbush@nattopharma.com
(+1) 609-454-2992 x 220

NattoPharma contact information:
Main Office: Kirkeveien 59B NO-1363 Høvik,Norway
North American Subsidary: 328 Amboy Ave.,Ste. D,Metuchen, NJ 08840
Tel: (+1) 609-454-2992
Created by:
Nutricon logo.
Search term:
Newsletter